






Supplementary Figure 1. Patient attrition chart.



BM, brain metastases; LDH, lactate dehydrogenase; MAP, managed access program; ULN, upper limit of normal.

Supplementary Figure 2. Baseline patient demographics and disease characteristics.





Median time to first recurrence was 17.9 months (range, 0–298), while median time to the most recent relapse was 28.2 months (range, 0–301).

^a Excluding patients with > 3 metastatic sites (without BM; $n = 78$)

^b Including patients with > 3 metastatic sites (without BM; $n = 78$)

AJCC, American Joint Committee on Cancer; BM, brain metastases; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; ULN, upper limit of normal.